Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials-Reference-Cited by-同舟云学术

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials

Published:2019-12-27 Issue:3 Volume:11 Page:640-646
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Investig

Author:

Tajima Naoko¹,Eiki Jun‐ichi²^ORCID,Okamoto Taro²,Okuyama Kotoba²,Kawashima Masaru³,Engel Samuel S⁴

Affiliation:

1. Jikei University School of Medicine Tokyo Japan

2. Medical Affairs, and Japan Development MSD K.K. Tokyo Japan

3. Medical Affairs ONO Pharmaceutical Co., Ltd. Osaka Japan

4. Clinical Research Merck & Co., Inc Kenilworth New Jersey USA

Funder

Merck

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdi.13182

Reference29 articles.

1. Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives

2. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

3. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus

4. Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes

5. Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sitagliptin as an Initial Therapy and Differential Regulations of Metabolic Parameters Depending on its Glycemic Response in Subjects with Type 2 Diabetes;Drug Research;2020-11-25